wholly to candidate civaparvovec we and owned Fabry treatment the announced Symposium. Sandy, afternoon call. data everyone you, at evaluating World updated XXth the our ST-XXX, afternoon, study Phase gene good therapy product or the Annual of isaralgagene X/X on for disease Thank from STAAR This our
data product treat ST-XXX in potential Fabry class supports profile from disease. in suffering Sandy presented best As opening, outlined the for today to patients his
two from who date, had patient cutoff been study the required the A the As as longest withdrawn XXXX and phases for α-Gal today. dose with of over enzyme successfully across supraphysiologic from has for patient of escalation XX exhibited activity years therapy sustained dose and ERT XX, ERT November expansion follow the five began supplemental replacement up. not patients on phase All escalation dose treatment the the resumption of the
kidney patients along have biopsy in the urine demonstrating now podocyte reduced we reduction loss. with Importantly, kidney cohort GbX of six substantial at in a data months evidence
ST-XXX actively We observed a the on we have truly health Based general improvement score has General as Survey. in mean clinically Health this point, believe and by statistically measured collective data SF-XX we're significant also leading the therapy of the potential to become we second potential which preparing a X in a important and trial, Phase gene expect XXXX. this for for begin indication, half to
the in little across two fourfold nearly treated XX XXXX XX, four for the a more of escalation into dose ranging cutoff of in November from in to doses mean patients supplemental Now, normal α-Gal activity phase digging detail patients escalation nine dose longest exhibited phase, years sustained all as the elevated the A treated data the date. fold for over the
and started supraphysiological withdrawn As successfully five remain α-Gal A on level ERT, I demonstrate outlined today. the ERT earlier, of continued who study withdrawal to following patients all were from ERT off activity
patient naive compared exhibited pesudo cohorts. activity and higher dose escalation patients the those X significantly naive levels of in the to A Cohort phase, patients For lower dose α-Gal in
dose XXXX following as had the first for extension to phase dosing vg/kg range XeXX of dose the increase A XX The in exhibited up cut-off at α-Gal normal last to the four As of activity patient within at XX, dosing. November in at measurement. the a rapid of the fourth date, weeks patient increased supplemental weeks date three sustained
participant males cut-off response female demonstrated study profile the first The date. to a as similar dosing the
assessment system. number the six from per PTC Fabry and a score in GbX blinded from in of baseline tubular paired baseline a pathologies PTC heart of dosing. who and demonstrated an organs, including two is patient of nervous months at per substance kidney, by inclusion of damage independently inclusion at for This and to biopsy inclusion result X.X an by clearance X.X GbX and adjudicated that XX% accumulate to plasma baseline high the nine cells or pathology. made was central the in fatty third images independent average impressive PTC The capillary multiple kidney kidney high months lyso-GbX section biopsy, we GbX digital exhibited patients, per after a can disease six inclusion level
and for biopsy In patient on GbX six exhibited loss Fabry of of support months The with eight, lower baseline, dosing GbX The potentially of lyso-GbX urinary activity nephropathy urinary XX% a effect plasma in inclusion progression which reduction nature on exhibited with patient inclusion an exhibited reduction a in podocyte to after six the PCT also favorable urine renal coupled α-Gal evidence reduction and this and along addition, significant lower in months. meaningful number indicates after months, therapy. up post increase inclusion dosing. Fabry XX% podocyte impact the loss level six loss kidney podocyte patient of in potential reduction upon of lyso-GbX this who in demonstrated of a provides decrease favorable the significant stable A impressive a nephropathy. This
mean changes baseline health patient with XX.X%. in addition, escalation of score XX a for significant general in were general week phase statistically In at the care health dose from increase
difference. point For score important X to change SF-XX any context, of clinically a a is X minimally,
naive to levels cutoff. data started XX% lyso-GbX experienced regard have continue lyso-GbX XX% to following patients level to until in a baseline the and and reduction pseudo decrease treatment two With for patient naive level for high, who of
highest per plasma in time dose For a the baseline observed XX% was started mil. the with where lyso-GbX reduction first XX nanogram levels the study in below level and
requiring ERT in had the For this ERT. within on patient escalation today. ERT of variability normally and elevated In range experienced no α-gal A began following lyso-GbX withdrawal level observed reception in the levels ERT symptom of of patients the who patient patient phase dose study remain with and plasma treated remain as the activity
in corticosteroid date, cutoff are detail events adverse than related immune in ST-XXX or treated no no of agents related other presented generally treatment the well events. adverse the tolerated patients treated serious administered. with As being available modulating data the This grade two Time to encourage was Hopkins this X have XXXX XX, prophylactic by investigators, one October February from presentation XX No been more to and doing Robert a AM of X our Eastern XXth would listen Eastern to the Dr. coming in a also session PM presentation study site poster Web you a These X are doing on Sangamo’s to Friday, page. presentation. Time. X and data We from greater
XXXX a of additional dosed XX expansion XX, we to date, in achieve patient October total. an cutoff phase patients four dosed have the the in Since total
was as to encephalopathy, from of male expansion We The and events adverse continue female screening. the Monitoring have In deemed December, patient XX dose withdrawn now two date. any No patient which patient the one has three in proceed study progressing fully a study may other in of and also recruiting, Safety are since total the the A an related and ERT. modifications. treatment. and additional XX with determined event active shoulder patient study to the of Committee observed similar possibly has the without sites grade additional have been recovered in patient extends phase serious in currently
our with our in the in XXXX the patient strategy. part and XXXX trial The of could of second dosing depending the alongside is half continue happen for anticipated the trial as progressing a strategy We plan interaction. on US to X Phase early commence regulatory as EU first potential first to of
reminder, factor the for of to mismatched dosing Phase TX-XXX to complete expected X/X living the not X/X STEADFAST commencement of prevention a In phase we in of the rejection from to in extension a CAR-Treg expect study, therapy two continue kidney cell As the XXXX be donor, well. study patient Phase which for HLA-AX for our gating first dose wholly the do is a the X. immune-mediated owned transplantation candidate Phase
kidney transplant. their patient has received third The
personalized XXXX. second actively manufactured have of the therapy full progressing. their of TX-XXX completion cohort the We the and study. the cohort expected in second This early will cell dosing mark quarter the Preparation is is of for successfully first
is patient anticipated manufacturing Dosing kidney first their progress. this is expected summer. in The to is transplant receive shortly and
but pre-screening is and Sandy top are enroll, our progressing safely this patients outlined, quickly in to priority. Additional as continue study
dose such, As to scheme find regulators with optimal we're dose escalation to the option discussing accelerate the efficacy. for
related sickle on zinc hemoglobin-F the a dose disease clinical were BIVVXXX, at preliminary treatment the five PRECIZN-X well events. we maintained continued show for cell. hemoglobin of with finger no gene ASH. sickle to data updated December, that that levels total nuclease cell to product for In patients The remain treated and tolerated generally to BIVVXXX the X/X from Phase patient presented of autologous therapy Moving up longest XX and months the data editing candidate cell treatment adverse across study
competitive following this was exhibited use first data present of of opportunity observed patient with Importantly, patient and deciliter, process. than the which with to level these significantly the manufacturing the is the from six fetal improved our is a on believe results, original dose process. we patient greater hemoglobin gram in five manufactured XX.X months a per BIVVXXX treatment. dose level hemoglobin a potential total product At treatment, XX% candidate Based
further on Treg working been potential efforts. from have our believe to The manufacturing which improvement the we across we improve we X which indicated, the Sandy process, has further product. manufacturing carrying learning are the to As Phase final
clinical dosing activity X We study, FDA. requirements and of patient manufacturing design package in the CMC progressed the and X/X have have with Phase other anticipation trial and in Phase seven the agreed also
as to are We this we not into a partner advance Phase help are can strong find patient X this further this trial to progress ourselves, we hopeful life. potential program collaboration can has disappointed therapy a who program but potential that potential believe improve
giroctogene first to dosing end look in Financial in the quarter hemophilia patient Pfizer severe an a of financial of Pfizer be Prathyusha, promising to our call support primary most Pfizer the X expected XXXX. forward trial by with complete the half half the overview assets their first for this Pfizer of Finally, a and Officer, over the is to that Prathyusha? investigational submission anticipating one are recently results. is Chief now with AFFINE moderately XXXX. for turn reiterated severe we gene the BLA A. will of to analysis to that pivotal therapy of of we in developing expect along our readout dosing progress the second I Phase of fitelparvovec, with potential XXXX
